CN103864752A - 甲磺酸伊马替尼的晶型及其制备方法 - Google Patents
甲磺酸伊马替尼的晶型及其制备方法 Download PDFInfo
- Publication number
- CN103864752A CN103864752A CN201410026320.4A CN201410026320A CN103864752A CN 103864752 A CN103864752 A CN 103864752A CN 201410026320 A CN201410026320 A CN 201410026320A CN 103864752 A CN103864752 A CN 103864752A
- Authority
- CN
- China
- Prior art keywords
- peak
- spectral line
- ray diffraction
- show
- relative intensity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 29
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 title abstract description 13
- 229960003685 imatinib mesylate Drugs 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 238000002441 X-ray diffraction Methods 0.000 claims description 31
- 230000003595 spectral effect Effects 0.000 claims description 30
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229960002411 imatinib Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- -1 compound imatinib mesylate Chemical class 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- ABOLPUDOABZSNW-UHFFFAOYSA-N N1CCNCC1.CC1=C(C=C(C(=O)O)C=C1)C(=O)O Chemical compound N1CCNCC1.CC1=C(C=C(C(=O)O)C=C1)C(=O)O ABOLPUDOABZSNW-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims (4)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010176726.2A CN102250063B (zh) | 2010-05-19 | 2010-05-19 | 甲磺酸伊马替尼的晶型及其制备方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010176726.2A Division CN102250063B (zh) | 2010-05-19 | 2010-05-19 | 甲磺酸伊马替尼的晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103864752A true CN103864752A (zh) | 2014-06-18 |
CN103864752B CN103864752B (zh) | 2015-11-25 |
Family
ID=44977673
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010176726.2A Expired - Fee Related CN102250063B (zh) | 2010-05-19 | 2010-05-19 | 甲磺酸伊马替尼的晶型及其制备方法 |
CN201410026320.4A Expired - Fee Related CN103864752B (zh) | 2010-05-19 | 2010-05-19 | 甲磺酸伊马替尼的晶型及其制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010176726.2A Expired - Fee Related CN102250063B (zh) | 2010-05-19 | 2010-05-19 | 甲磺酸伊马替尼的晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN102250063B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114957206A (zh) * | 2022-04-11 | 2022-08-30 | 中国药科大学 | 伊马替尼共晶及其制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104513227A (zh) * | 2013-09-29 | 2015-04-15 | 山东新时代药业有限公司 | 一种甲磺酸伊马替尼α晶型的生产方法 |
CN105566291B (zh) * | 2016-02-02 | 2018-06-01 | 连云港恒运药业有限公司 | 制备甲磺酸伊马替尼晶型的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004099186A1 (en) * | 2003-05-06 | 2004-11-18 | Il Yang Pharm Co., Ltd. | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof |
WO2006054314A1 (en) * | 2004-11-17 | 2006-05-26 | Natco Pharma Limited | Polymorphic forms of imatinib mesylate |
US20060173182A1 (en) * | 2003-02-18 | 2006-08-03 | Cipla Limited | Process of preparing imatinib and imatinib prepared thereby |
CN101016293A (zh) * | 2007-02-14 | 2007-08-15 | 杭州盛美医药科技开发有限公司 | 一种伊马替尼的制备方法 |
US20080275055A1 (en) * | 2007-05-02 | 2008-11-06 | Chemagis Ltd. | Imatinib production process |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101641345A (zh) * | 2006-10-26 | 2010-02-03 | 西科尔公司 | 晶体和无定形伊马替尼碱、甲磺酸伊马替尼及其制备方法 |
CN102040587A (zh) * | 2009-10-26 | 2011-05-04 | 韩南银 | 一种甲磺酸伊马替尼的制备方法 |
CN101735197B (zh) * | 2009-12-18 | 2013-06-19 | 天津市炜杰科技有限公司 | 一种伊马替尼的合成方法 |
-
2010
- 2010-05-19 CN CN201010176726.2A patent/CN102250063B/zh not_active Expired - Fee Related
- 2010-05-19 CN CN201410026320.4A patent/CN103864752B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060173182A1 (en) * | 2003-02-18 | 2006-08-03 | Cipla Limited | Process of preparing imatinib and imatinib prepared thereby |
WO2004099186A1 (en) * | 2003-05-06 | 2004-11-18 | Il Yang Pharm Co., Ltd. | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof |
WO2006054314A1 (en) * | 2004-11-17 | 2006-05-26 | Natco Pharma Limited | Polymorphic forms of imatinib mesylate |
CN101016293A (zh) * | 2007-02-14 | 2007-08-15 | 杭州盛美医药科技开发有限公司 | 一种伊马替尼的制备方法 |
US20080275055A1 (en) * | 2007-05-02 | 2008-11-06 | Chemagis Ltd. | Imatinib production process |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114957206A (zh) * | 2022-04-11 | 2022-08-30 | 中国药科大学 | 伊马替尼共晶及其制备方法 |
CN114957206B (zh) * | 2022-04-11 | 2024-02-27 | 中国药科大学 | 伊马替尼共晶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102250063B (zh) | 2014-10-22 |
CN102250063A (zh) | 2011-11-23 |
CN103864752B (zh) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102325775B1 (ko) | 5-클로로-n2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-n4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태 | |
ES2638144T3 (es) | Bencilpirazoles sustituidos | |
TW402596B (en) | 4-anilino-quinazoline derivatives for use in treating, inhibiting the growth of or eradicating neoplasms, preparation method and pharmaceutical composition thereof | |
JP6170146B2 (ja) | チロシンキナーゼ阻害剤二マレイン酸塩のi型結晶およびその製造法 | |
JP5118024B2 (ja) | 有機化合物の合成方法 | |
TW200530195A (en) | Benzimidazole derivatives: preparation and pharmaceutical applications | |
JP2010526056A (ja) | イマチニブの製造方法 | |
AU5567000A (en) | Alpha1b-adrenergic receptor antagonists | |
CN102250063B (zh) | 甲磺酸伊马替尼的晶型及其制备方法 | |
CA2748319A1 (en) | Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation | |
CN102190649B (zh) | 一种制备α型甲磺酸伊马替尼的方法 | |
AU2013332205A1 (en) | Solid forms of Nilotinib hydrochloride | |
CN101948437A (zh) | 一种盐酸苯达莫司汀的精制方法 | |
JP2017521489A (ja) | ピリミジン化合物およびその使用方法 | |
EP3189045A2 (en) | Novel salts of nilotinib and polymorphs thereof | |
WO2016074597A1 (zh) | 钾离子竞争性酸阻滞剂的晶型及其制备方法 | |
WO2012004801A1 (en) | Process for imatinib mesylate | |
CN111617083B (zh) | 甲氧基取代苯基酰胺类氨基嘧啶衍生物的应用 | |
CN115385845A (zh) | 一种吡咯磺酸类化合物盐型制备 | |
CN111620854A (zh) | 4-氨基嘧啶取代的苯基酰胺类化合物及其制备方法 | |
RU2015130222A (ru) | Кристаллическая форма соединения, используемая в качестве антагониста минералокортикоидного рецептора, и способ ее получения | |
CN102924448A (zh) | 生物碱cryptolepine类似物吲哚并喹啉酸化合物及制备方法 | |
TW379224B (en) | Urea derivatives | |
JP6871255B2 (ja) | ゲフィチニブの結晶形aを製造する方法 | |
WO2010057430A1 (zh) | 厄罗替尼盐酸盐的多晶型l、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU HANSOH MEDICAL GROUP CO.,LTD. Free format text: FORMER OWNER: JIANGSU HANSOH MEDICAL RESEARCH INSTITUTE CO., LTD. Effective date: 20140701 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140701 Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: JIANGSU HANSOH MEDICINE INSTITUTE Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee after: Jiangsu best Pharmaceutical Co.,Ltd. Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee before: Jiangsu best Pharmaceutical Co.,Ltd. Patentee before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20160315 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 |
|
CF01 | Termination of patent right due to non-payment of annual fee |